HIV Clinical Trials | HIV Vaccine Trials and Progress for 2021: Nearly 40 years have move since the first HIV cases were found in the US. According to HIV.gov, there were 1.7 million new HIV infections in 2019.
Despite ongoing research and trials, there is no HIV vaccine available as of December 2021. Less stigmatizing approaches have increased lifespans while avoiding HIV transmission. Vaccination is the only viable strategy to eliminate the epidemic.
Despite several obstacles, the development of an HIV vaccine continues. It has even aided in the creation of vaccines for other diseases. Here’s the current status of HIV vaccine trials and expectations in 2022.
HIV Clinical Trials | HIV Vaccine Trials and Progress for 2021
AIDS Vaccine Progress And Concerns
After decades of research and clinical testing, it may be difficult to accept that other recent infectious diseases have new vaccinations but not HIV. Lesser-known reasons include:
For example, HIV has many evolving variations. It is probably owing to their immunity-evading abilities. The virus can spread unintentionally 1–2 weeks after exposure because it “hides” in the body.
The effectiveness of non-vaccine preventative measures like PrEP has made it challenging to construct accurate HIV vaccine efficacy trials. Despite these obstacles, research and development of an HIV vaccine have made significant progress.
The “RV144 Thai trial” from 2003 to 2009 found the best success in humans. The two-dose vaccine experiment showed a 31 percent trusted Source effectiveness rate.
As we’ll see later, the perceived “failed” attempts to develop an HIV vaccine have paved the way for other vaccinations that protect against other infectious diseases. Consider the COVID-19 vaccination.
Trials Of HIV Vaccines In 2021
Many other HIV vaccine trials have used the RV144 trial’s lessons. The HVTN 702 (Uhambo) experiment, which lasted from 2016 to 2021, was one promising trial. Less efficacy than the RV144, presumably due to lower protein dosages.
Still, the HVTN 702 study spawned two novel HIV vaccine candidates currently in clinical studies. These are HVTN 706 (Mosaico) and 705 (Imbokodo).
Both Imbokodo and Mosaico require two shots, each carrying a separate vaccination, administered monthly for six months. Imbokodo only involves women from five nations in Sub-Saharan Africa. However, Mosaico is currently testing in the US and seven other countries.
HIV Vaccine Trials For 2022 Are In Progress
Researchers and developers will likely focal point on the two late-stage trials — Mosaico and Imbokodo — in 2022. The National Institutes of Health stated that Imbokodo does not provide “sufficient protection against HIV in women trusted Source” as of August 2021.
While these HIV vaccine trials could fail, they appear to be the most promising. Also, while HIV vaccine trials have fueled COVID-19 mRNA vaccine development, one business plans to try an mRNA HIV vaccine. Moderna and universities are leading this study, recruiting in December 2021.
Like Moderna’s mRNA COVID-19 vaccine, the Moderna mRNA vaccine could help prevent numerous HIV variants. Their job is to create protective proteins for the immune system. Since the Mosaico and Imbokodo vaccine studies are nearing completion, no more recruits are needed.
Read the requirements and talk to your doctor if you want to be part of the future Moderna mRNA HIV vaccine study. There are ongoing studies for new HIV drugs, health issues, and more. ClinicalTrials.gov keeps track of new trials and recruitment opportunities. Consult your doctor before declaring yourself eligible for a clinical trial.
Has The HIV Vaccine Had An Impact On The COVID-19 Vaccines?
While no HIV vaccine has yet been developed, scientists warn against any illusions that decades of work have been wasted. Previous research and testing have also contributed to the discovery of vaccinations for other infectious diseases.
COVID-19 (SARS-CoV-2) vaccinations have a notable “spill-over” effect. Vaccines for numerous infectious diseases have emerged from HIV vaccine research, including:
- SARS (severe acute respiratory syndrome) (also known as SARS-CoV-1)
- The human papillomavirus (HPV)
- Hemorrhagic Ebola fever (Ebola)
- Respiratory syndrome in the Middle East (MERS)
The development of influenza (flu virus) vaccine contributed to the vaccinations indicated above.
Collaborations were vital in the rapid development of COVID-19 vaccines. It includes businesses, governments, clinics, and universities. One such alliance is Pfizer-BioNTech. Researchers anticipate that the COVID-19 pandemic partnerships will motivate similar efforts to develop an HIV vaccine sooner rather than later.
The Bottom Line
There is no HIV vaccine, but researchers believe one is on the way. Two late-stage trials and a Moderna mRNA trial will continue till 2022. The following steps will be depending on the results of these experiments.
Until then, use current options, such as PrEP and PEP drugs, and practice safer sex with a condom or other barrier measures, especially in high-risk scenarios. Discuss with your doctor how you might reduce your risk and any concerns.
PrEP can be prescribed by any licensed health care professional, regardless of specialization in infectious diseases or HIV medicine. According to ACA, PReP must be covered by practically all insurance policies.